ISSN: 0973-7510

E-ISSN: 2581-690X

Review Article | Open Access
Hiren A. Dhameliya, Vasudev R. Thakkar, Gauravi N. Trivedi, Sureshkumar N. Mesara and R.B. Subramanian
Post Graduate Department of Biosciences, Centre of Advanced Study in Bioresource Technology, Sardar Patel University, Satellite Campus, Bakrol-Vadtal Road, Bakrol, Anand – 388 315, Gujarat, India.
J Pure Appl Microbiol. 2020;14(suppl 1):861-867 | Article Number: 6331
Received: 05/05/2020 | Accepted: 14/05/2020 | Published: 15/05/2020
Abstract

Rapidly spreading outbreak of the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is causing serious health concerns worldwide. It started as an epidemic in Wuhan, Hubei province, central China, and has now become a pandemic, spreading over most of the continents of the planet. The major clinical symptoms of the infection are dry cough, fever, pneumonia, respiratory failure, hypoxia, and in certain cases, even death. Alveolar damage and respiratory system failure are observed in severe cases. Initial mild infection leads to activation of the immune system in the lungs and accumulation of various inflammatory cells and molecules. At a later phase during the infection, a “cytokine storm” causes an Acute Respiratory Distress Syndrome (ARDS), leading to an increase in the production of pro-inflammatory cytokines, migration of a large number of immune cells to the site of infection, and ultimately pulmonary damage. The rapid and uncontrolled outbreak requires putative therapeutic drugs for treatment of patients suffering from COVID-19. Amongst the currently used antiviral drugs, such as hydroxychloroquine, lopinavir, remdesivir etc. we would like to present an update on another effective drug, pentoxifylline. Pentoxifylline has anti-inflammatory, immunomodulatory, anti-viral, and bronchodilatory properties. Pentoxifylline is known to reduce cytokine production, immune cell migration, and suppress certain signal transduction pathways (e.g. NF-κβ and STAT3). Thus, it minimizes inflammatory damage in the lung tissues.

Keywords

Anti-inflammatory, Anti-viral, COVID-19, Cytokines, Pentoxifylline, SARS-CoV-2

Article Metrics

Article View: 440

Share This Article

© The Author(s) 2020. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.